Disclosure Of Entity's Operating Segments [Text Block]

Zealand Pharma - Filing #5889383

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Disclosure of entity's operating segments [text block]	2	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue	62,691,000 DKK	—	—	—	—	—	—	342,788,000 DKK	—	—	—	—
Tax expense (income)	4,617,000 DKK	—	—	—	—	—	—	5,126,000 DKK	—	—	—	—
Profit (loss) before tax	1,083,445,000 DKK	—	—	—	—	—	—	708,865,000 DKK	—	—	—	—
Profit (loss)	1,078,828,000 DKK	- DKK	- DKK	—	- DKK	1,078,828,000 DKK	- DKK	703,739,000 DKK	—	- DKK	703,739,000 DKK	- DKK
Assets	—	—	—	9,505,600,000 DKK	—	—	—	—	1,979,993,000 DKK	—	—	—
Liabilities	—	—	—	888,858,000 DKK	—	—	—	—	387,154,000 DKK	—	—	—
Cash flows from (used in) operating activities	930,816,000 DKK	—	—	—	—	—	—	425,668,000 DKK	—	—	—	—
Cash flows from (used in) investing activities	7,332,915,000 DKK	—	—	—	—	—	—	1,094,033,000 DKK	—	—	—	—
Cash flows from (used in) financing activities	8,288,491,000 DKK	—	—	—	—	—	—	907,014,000 DKK	—	—	—	—
Disclosure of products and services [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of major customers [abstract]
Disclosure of major customers [line items]